ADVFN - Advanced Financial Network.
HOME» NYSE » B » BCR Stock Price » BCR Stock News

Bard C R Share News

 Bard (c.r.), Inc. Stock Price
BCR Stock Price
 Bard (c.r.), Inc. Stock Chart
BCR Stock Chart
 Bard (c.r.), Inc. Stock News
BCR Stock News
 Bard (c.r.), Inc. Company Information
BCR Company Information
 Bard (c.r.), Inc. Stock Trades
BCR Stock Trades

CR Bard Swings To 2Q Loss On Legal Settlement Charge

DOW JONES NEWSWIRES Medical-device maker C.R. Bard Inc. (BCR) swung to a second-quarter loss as a previously disclosed $181 million after-tax legal settlement charge masked revenue growth across all product categories. Shares slid 7.7% to $104 in after-hours trading, as the sales growth in constant currency terms narrowly missed the company's April guidance. A rebound in spending in the health-care sector has driven renewed profits at companies like C.R. Bard, which has reported solid revenue growth on a strong performance in the vascular business, its largest by revenue. In the latest quarter, adjusted results grew amid a strong performance in the vascular and oncology segments. Last month, the company warned it would record a charge after it reached a $184 million agreement to settle most of the lawsuits involving faulty hernia repair products it started pulling from the market years ago. On Thursday, C.R. Bard reported a quarterly loss of $47.8 million, or 55 cents a share, compared with a prior-year profit of $124.7 million, or $1.29 a share. Excluding the legal settlement in the latest quarter and other impacts, adjusted earnings rose to $1.57 from $1.39 a share. Revenue jumped 7.6% to $725 million and was up 5% in constant currency. The company in April projected adjusted earnings of $1.53 to $1.57 a share and constant currency sales growth of 6% to 8%. Gross margin narrowed to 62% from 62.7%. Sales in the urology segment climbed 2%, while vascular business sales increased 15%. Oncology and surgical specialities revenues jumped 8% and 4%, respectively. -By John Kell, Dow Jones Newswires; 212-416-2480; john.kell@dowjones.com

Stock News for Bard C R (BCR)
DateTimeHeadline
11/15/201308:47:28ValueAct Capital Management LP 3Q 13F: Holdings As Of Sep 30
11/15/201308:18:57Farallon Capital Management 3Q 13F: Largest Eliminations
11/15/201308:18:52Farallon Capital Management 3Q 13F: Holdings As Of Sep 30
11/15/201307:07:30Two Sigma Investments 3Q 13F: Largest Eliminations
11/15/201307:07:27Two Sigma Investments 3Q 13F: Largest Sales
11/15/201307:07:27Two Sigma Investments 3Q 13F: Largest Purchases
11/15/201307:07:27Two Sigma Investments 3Q 13F: Largest Eliminations -2-
11/15/201307:04:50Bridgewater Associates LP 3Q 13F: Largest -2-
11/15/201307:04:50Bridgewater Associates LP 3Q 13F: Holdings As Of -2-
11/15/201307:04:50Bridgewater Associates LP 3Q 13F: Largest Purchases
11/15/201307:04:49Bridgewater Associates LP 3Q 13F: Holdings As Of Sep 30
09/04/201309:35:09U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH
06/28/201310:54:22Boston Scientific to Buy C.R. Bard Unit for $275 Million
10/25/201218:32:16High-Grade-Bond Market Absorbs $3.9 Billion of New Deals
06/05/201212:53:24J&J to Stop Selling Surgical Mesh Amid Lawsuits, Concerns -AP
04/21/201200:20:37MARKET SNAPSHOT: U.S. Stock Gains Hinge On Apple, Blue-chip Results
01/04/201216:13:14FDA Orders Post-Market Testing Of Surgical Mesh Amid Safety Concerns
12/21/201109:10:36US Stock Futures: HOT STOCKS TO WATCH
10/26/201107:57:35US Stock Futures Higher On Optimism Ahead Of EU Summit
09/14/201114:52:55Erste Group Bank To Buy 24.12% Stake In Romania Unit

Bard C R and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad